检索结果-南通市图书馆

World Journal of Gastroenterology 2024年第22期30卷 2839-2842页

作者： Chen-Xiao Huang Xiao-Dong Zhou calvin q pan Ming-Hua Zheng Metabolic Dysfunction-Associated Fatty Liver Disease Research Center Department of HepatologyThe First Affiliated Hospital of Wenzhou Medical UniversityWenzhou 325000Zhejiang ProvinceChina Department of Cardiovascular Medicine The Key Laboratory of Cardiovascular Diseases of WenzhouThe First Affiliated Hospital of Wenzhou Medical UniversityWenzhou 325000Zhejiang ProvinceChina Division of Gastroenterology and Hepatology Department of MedicineNew York University Langone HealthNew York University Grossman School of MedicineNew YorkNY 11355United States Institute of Hepatology Wenzhou Medical UniversityKey Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang ProvinceWenzhou 325000Zhejiang ProvinceChina

Metabolic dysfunction-associated fatty liver disease(MAFLD)is the most prevalent chronic liver condition *** liver enzyme-based screening methods have limitations that may missed diagnoses and treatment *** Chen et al,the risk of developing MAFLD remains elevated even when alanine aminotransferase levels fall within the normal ***,there is an urgent need for advanced diagnostic techniques and updated algorithms to enhance the accuracy of MAFLD diagnosis and enable early *** paper proposes two potential screening methods for identifying individuals who may be at risk of developing MAFLD:Lowering these thresholds and promoting the use of noninvasive liver fibrosis scores.

关键词： Metabolic dysfunction-associated fatty liver disease Non-alcoholic fatty liver disease Alanine aminotransferase Liver enzymes Screening Noninvasive liver fibrosis scores

Risk assessment and management of hepatitis B reactivation from direct-acting antivirals for hepatitis C

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Liver Research 2019年第2期3卷 75-79页

作者： Maureen Whitsett David M.Feldman calvin q.pan Division of Gastroenterology and Hepatology Department of MedicineNYU Langone HealthNew York University School of MedicineNew YorkNYUSA

Although hepatitis B virus(HBV)reactivation has been reported in hepatitis C patients who received interferon therapy,rare cases of HBV reactivation occur in the context of direct-acting antiviral(DAA)agent therapy for treatment of hepatitis C virus(HCV)*** studies observed that the reactivations were predominantly in hepatitis B surface antigen(HBsAg)positive patients,but reactivation can rarely occur in patients who are HBsAg negative and hepatitis B core antibody(HBcAb)*** severity of an HBV flare *** some cases,severe liver injury or fulminant hepatic failure may *** reactivation may occur regardless of HCV genotype and type of DAA *** onset of HBV reactivation can range from 4 to 48 weeks after initiating DAA *** patients may have undetectable levels of HBV deoxyribonucleic acid(DNA)prior to DAA ***-emptive antiviral therapy for HBV should be considered in HBsAg-positive patients with high levels of viremia who are not receiving HBV *** HBV DNA viral load is less than the guideline criteria for HBV treatment,one should consider pre-emptive HBV antiviral versus HBV DNA monitoring during DAA *** patients who are HBsAg negative but HBcAb positive,close monitoring of serum alanine aminotransferase(ALT)levels during/post-treatment is highly *** current review summarizes the recommendations of different society guidelines and discusses the appropriate management strategies in various patient profiles.

关键词： Co-infection Treatment induced flares Hepatitis B exacerbation Hepatitis C therapy Prevention of disease reactivation

Efficacy and Safety of Sofosbuvir-based Regimens in Hepatitis C Patients With Decompensated Cirrhosis:A Systematic Review and Meta-analysis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Clinical and Translational Hepatology 2023年第1期11卷 144-155页

作者： Wenyan Zhang Jing Zhang Shan Tang Yali Liu Xiaofei Du Lixia qiu Menglu Liu Haibin Yu calvin q.pan Beijing Youan Hospital Capital Medical UniversityBeijingChina Division of Gastroenterology and Hepatology Department of MedicineNYU Langone HealthNYU Grossman School of MedicineNew YorkUSA

Background and Aims:Decompensated cirrhotic patients with hepatitis C(HCV)are often under-represented in clinical *** aimed to evaluate pooled data on the efficacy and safety of sofosbuvir(SOF)-based regimens in these ***:We conducted a systemic review and meta-analysis by searching multiple databases for studies published from October 2010 to October *** of interest were sustained virologic response(SVR)and safety of SOFbased regimens in decompensated HCV *** reviewers independently performed the study selection and data ***:We included 33 studies that enrolled 5,302 HCV *** pooled SVR rate in decompensated patients with SOF-based regimens was 85.1%(95%CI:82.8–87.3).Patients on SOF/velpatasvir±ribavirin achieved a significantly higher SVR(91.0%,95%CI:87.7–93.9)than that of SOF/ledipasvir±ribavirin[(86.3%,95%CI:84.6–87.8);p=0.004],or on SOF/daclatasvir±ribavirin(82.4%,95%CI:78.2–86.2%;pquency of adverse events from 52.9%(95%CI:28.0–77.1)to 89.2%(95%CI:68.1–99.9)and frequency of severe *** pooled incidence of hepatocellular carcinoma and case-fatality of decompensated patients were 3.1%(95%CI:1.5–5.0)and 4.6%(95%CI:3.1–6.3),*** overall heterogeneity was *** was no publication ***:The analysis found that 12 weeks of SOF/velpatasvir without ribavirin is the preferred therapy,with a significantly higher SVR compared with other SOF-based regimens in decompensated HCV patients.

关键词： Direct-acting antiviral HCV liver failure Sustained virologic response Ribavirin

Acute on chronic hepatitis B liver failure:From Concept to Consensus

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Acute on chronic hepatitis B liver failure:From Concept to C...

Pregnancy and fetal outcomes of chronic hepatitis C mothers with viremia in China

第6届全国疑难及重症肝病大会

作者： calvin q.pan Division of Liver Diseases Mount Sinai School of Medicine

Acute on Chronic Liver Failure(ACLF)was first used in 1995 to describe a condition in which rapidly deteriorating liver function from acute insult to the liver in patients with ongoing or chronic liver ***,the clinica...

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2022年第34期28卷 5023-5035页

作者： calvin q pan Bao-Shen Zhu Jian-Ping Xu Jian-Xia Li Li-Juan Sun Hong-Xia Tian Xi-Hong Zhang Su-Wen Li Er-Hei Dai Center for Liver Diseases Beijing Ditan HospitalCapital Medical UniversityBeijing 100015China Division of Gastroenterology and Hepatology Department of MedicineNYU Langone HealthNYU School of MedicineFlushingNY 11355United States Department of Obstetrics and Gynecology The Fifth Hospital of ShijiazhuangHebei Medical UniversityShijiazhuang 050021Hebei ProvinceChina School of Public Health North China University of Science and TechnologyTangshan 063210Hebei ProvinceChina Division of Liver Disease Department of MedicineThe Fifth Hospital of ShijiazhuangHebei Medical UniversityShijiazhuang 050021Hebei ProvinceChina

BACKGROUND Data that assess maternal and infant outcomes in hepatitis C virus(HCV)-infected mothers are *** To investigate the frequency of complications and the associated risk *** We performed a cohort study to compare pregnancy and fetal outcomes of HCVviremic mothers with those of healthy *** factors were analyzed with logistic *** Among 112 consecutive HCV antibody-positive mothers screened,we enrolled 79 viremic *** randomly selected 115 healthy mothers from the birth registry as the *** to healthy mothers,HCV mothers had a significantly higher frequency of anemia[2.6%(3/115)vs 19.0%(15/79),Pquired caesarian section[27.8%(32/115)vs 48.1%(38/79),P=0.004],and nuchal cords[9.6%(11/115)vs 34.2%(27/79),Pquire caesarian sections(adjusted OR:2.6,95%CI:1.4-4.9),and have nuchal cords(adjusted OR:5.6,95%CI:2.4-13.0).Their neonates were also more likely to have smaller head circumferences(adjusted OR:2.1,95%CI:1.1-4.3)and lower birth weights than the average(≤3250 gms)with an adjusted OR of 2.2(95%CI:1.2-4.0).The vertical transmission rate was 1%in HCV-infected *** Maternal HCV infections may associate with pregnancy and obstetric *** demonstrated a previously unreported association between maternal HCV viremia and a smaller neonatal head circumference,suggesting fetal growth restriction.

关键词： Hepatitis C virus viremia Mother-to-child transmission Pregnancy complications Maternal health Infant hepatitis C virus infection

乙型肝炎病毒母婴传播及其阻断研究的现状与存在问题

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中华肝脏病杂志 2010年第7期18卷 556-558页

作者：邹怀宾陈煜张华段钟平李杰庄辉梁晓峰 calvin q.pan 首都医科大学附属北京佑安医院人工肝中心北京100069 首都医科大学附属北京佑安医院肝病产科北京100069 北京大学医学部病原生物学系中国疾病预防控制中心免疫规划中心 Mount Sinai School of Medicine New York

HBV可经血液、母婴、性接触等多种途径传播,其中母婴传播是我国HBV传播的主要途径之一.乙型肝炎母婴阻断是指通过产前、产时,产后采取一系列措施对新生儿进行保护以减少感染HBV机会的方法.近年来,HBV的母婴阻断取得了较好效果,总体阻断... 详细信息

HBV可经血液、母婴、性接触等多种途径传播,其中母婴传播是我国HBV传播的主要途径之一.乙型肝炎母婴阻断是指通过产前、产时,产后采取一系列措施对新生儿进行保护以减少感染HBV机会的方法.近年来,HBV的母婴阻断取得了较好效果,总体阻断成功率约在90%以上,但仍有一定的失败率,在相关机制、方案优化等方面仍面临一些亟待解决的问题.

关键词：肝炎病毒,乙型母亲婴儿疫苗

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2015年第18期21卷 5524-5531页

作者： calvin q pan Sing Chan Huy Trinh Alan Yao Ho Bae Lillian Lou Division of Gastroenterology Department of Medicine New York University Langone Medical Center New York University School of Medicine Sing Chan Endoscopy FlushingNew York City NY 11355 United States San Jose Gastroenterology San Jose Ca 95128 United States AE and LY Medical associates Flushing New York City NY 11355 United States Asian Pacific Liver Center St. Vincent Medical Center Nexus Development Palo alto Ca 94301 United States

AIM:To compare the efficacy and safety of tenofovir disoproxil fumarate(TDF)in Asian and non-Asian chronic hepatitis B(CHB)***:The efficacy and safety of the initial 48wk of treatment with TDF was compared in a posthoc analysis of combined data from 217 Asians and299 non-Asians included in Studies 102 and 103and a post-approval,open-label trial(Study 123).Patient groups were compared according to baseline hepatitis B e antigen(HBe Ag)status and viral *** main outcome measures included the proportion of patients who achieved a hepatitis B virus(HBV)DNA level<400 copies/m L at Week 48 of *** measures included:HBV DNA and alanine aminotransaminase(ALT)levels over time;proportion of patients with normal ALT levels;proportion of patients with HBe Ag loss/seroconversion and proportion of patients with hepatitis B surface antigen loss/seroconversion;changes in liver *** and tolerability were evaluated by the occurrence of adverse events(AEs),serious AEs,laboratory abnormalities,discontinuation of the study drug due to AEs,or *** primary efficacy and safety analysis set included all patients who were randomly assigned to treatment and received at least one dose of study ***:At week 48,similar proportions of Asians and non-Asians reached HBV DNA<400 copies/m L(96%of Asian and 97%of non-Asian patients with HBe Ag-negative CHB and 83%of Asian and 79%of non-Asian patients with HBe Ag-positive CHB had HBV DNA)and normal ALT(78%of Asian and 81%of nonAsian patients with HBe Ag-negative CHB and 71%of Asian and 74%of non-Asian patients with HBe Agpositive CHB had normal ALT).On-treatment HBV DNA decline rates were similar between Asians and nonAsians regardless of baseline HBe Ag status and *** DNA decline during the first four weeks was2.9 log10 copies/m L in HBe Ag-negative Asians and nonAsians,and in HBe Ag-positive non-Asians,and 3.1log10 copies/m L in HBe Ag-positive *** Ag loss and seroconversion wa

关键词： Chronic hepatitis B Tenofovir Asian patients Fibrosis High viral load

代偿期丙型肝炎肝硬化患者抗病毒治疗的临床研究

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中华肝脏病杂志 2017年第11期25卷 827-833页

作者：谢志伟李剑萍关玉娟张霞意郭凤霞陈彬彬 calvin q. pan 广州医科大学附属市八人民医院肝病二科 510060 美国纽约大学医学院朗格尼医学中心胃肠病和肝病科 11355

目的通过回顾性研究代偿期丙型肝炎肝硬化患者，探讨抗病毒治疗对肝硬化进展的影响并寻找肝硬化进展的预测因素。方法将2004年至2015年就诊的代偿期丙型肝炎肝硬化患者分为3组：治疗后获得持续病毒学应答（SVR）组、未获得SVR（NSVR）... 详细信息

目的通过回顾性研究代偿期丙型肝炎肝硬化患者，探讨抗病毒治疗对肝硬化进展的影响并寻找肝硬化进展的预测因素。方法将2004年至2015年就诊的代偿期丙型肝炎肝硬化患者分为3组：治疗后获得持续病毒学应答（SVR）组、未获得SVR（NSVR）组和未治疗组。通过分析对比伴或不伴肝硬化进展的患者基线特征，寻找肝硬化进展预测因素；同时研究血小板计数、脾脏大小、终末期肝病模型（MELD）评分、序贯器官衰竭评估（SOFA）评分及Child-Turotte-Pugh（CTP）评分的改变，对比3组肝癌发生率。据资料不同分别采用One-Way ANOVA检验、Kruskal-Wallis H检验、两样本t检验、χ^2检验、多因素logistic回归分析。结果共纳入89例代偿期肝硬化患者，42例接受干扰素联合利巴韦林抗病毒治疗（30例接受聚乙二醇干扰素仅和12例接受普通干扰素），47例未接受任何抗病毒治疗。在接受干扰素联合利巴韦林抗病毒治疗患者中，20例获得SVR，22例未获得SVR。与基线值相比较，SVR组和NSVR组血小板计数分别增加（44．93±32．66）×10^9／L和（9．73±28．83）×10^9／L，未治疗组血小板计数下降（19．76±54．5）×10^9／L，三组血小板计数的改变差异有统计学意义（F=14．731，P〈0．001）；SVR组脾脏缩小（0．91±1．09）cm，而NSVR组及未治疗组脾脏分别增大（0．20±0．84）cm和（1．11±1．69）cm，三组脾脏变化差异有统计学意义（F=14．943，P〈0．001）；而三组MELD评分、SOFA评分及CTP评分的变化无明显差异（P〉0．05）。SVR组、NSVR组和未治疗组进展为肝癌的患者例数分别为1例（5．00％）、5例（22．73％）和6例（12．77％），差异有统计学意义（χ^2=13．787，P=0．001）。单因素分析提示SVR、HCVRNA、总胆红素、白蛋白是疾病进展的预测因素，多因素logistic回归分析提示SVR及总胆红素是疾病进展的预测因素。结论干扰素联合利巴韦林治疗代偿期丙型肝炎肝硬化的临床疗效确切，具有较好的近期和远期疗效。

关键词：肝炎,丙型肝硬化代偿期干扰素α 利巴韦林

恩替卡韦抗病毒治疗的乙型肝炎失代偿期肝硬化患者并发症的再代偿

在线全文

学校读者我要写书评

暂无评论

中华肝脏病杂志 2023年第7期31卷 692-697页

作者：张婷邓优康海燕向慧玲南月敏胡瑾华孟庆华房继莲胥婕王晓明赵红 calvin q.pan 贾继东徐小元谢雯首都医科大学附属北京地坛医院肝病中心北京100015 石家庄市第五医院感染六科石家庄050021 天津市第三中心医院消化肝病科天津300170 河北医科大学第三医院中西医结合肝病科石家庄050051 中国人民解放军总医院第五医学中心肝病医学部北京京100071 首都医科大学附属北京佑安医院肝病重症医学科北京100069 北京大学人民医院北京大学肝病研究所北京100044 北京大学第三医院感染疾病科北京100191 首都医科大学附属北京友谊医院肝病中心北京100050 北京大学第一医院消化科北京100034

目的分析恩替卡韦抗病毒治疗后慢性乙型肝炎失代偿期肝硬化患者再代偿的发生情况。方法前瞻性纳入以腹水为首发表现的慢性乙型肝炎失代偿期肝硬化患者,接受恩替卡韦治疗120周,每24周对患者进行1次随访(包括临床终点事件、血液学及影像... 详细信息

目的分析恩替卡韦抗病毒治疗后慢性乙型肝炎失代偿期肝硬化患者再代偿的发生情况。方法前瞻性纳入以腹水为首发表现的慢性乙型肝炎失代偿期肝硬化患者,接受恩替卡韦治疗120周,每24周对患者进行1次随访(包括临床终点事件、血液学及影像学指标等),根据Baveno VII标准计算再代偿率。计量资料组间比较采用Student t检验或Mann-whitney U检验;计数资料的组间比较采用χ^(2)检验或Fisher确切概率法。结果在入组的320例患者中,283例完成了120周的随访,其中92.2%(261/283)的患者实现了病毒学应答。(HBV DNA15的患者积极抗病毒治疗后实现再代偿的概率高于基线MELD评分≤15的患者[67.6%(50/74)与52.2%(109/209),χ^(2)=5.275,P=0.029]。结论乙型肝炎失代偿期肝硬化患者抗病毒治疗可以显著改善预后,大部分患者(56.2%)可以实现再代偿,基线病情较重的患者实现再代偿的概率并不低于其他患者。

关键词：慢性乙型肝炎失代偿期肝硬化再代偿

Polynomial-Time Key-Recovery Attacks Against NTRURe Encrypt from ASIACCS'15

在线全文

学校读者我要写书评

暂无评论

Journal of Systems Science & Complexity 2024年第3期37卷 1308-1325页

作者： LIU Zhen pan Yanbin ZHENG Jinwei School of Cyber Science and Technology Hubei Key Laboratory of Applied MathematicsHubei UniversityWuhan 430062China Key Laboratory of Mathematics Mechanization Academy of Mathematics and Systems ScienceChinese Academy of SciencesBeijing 100190China School of Mathematical Sciences University of Chinese Academy of SciencesBeijing 100190China

In ASIACCS 2015, Nu nez, et al. proposed a proxy re-encryption scheme, named NTRURe Encrypt, based on NTRU, which allows a proxy to translate ciphertext under the delegator’s public key into a re-encrypted ciphertext that can be decrypted correctly by delegatee’s private key. Because of the potential resistance to quantum algorithm, high efficiency and various applications in real life,NTRURe Encrypt has drawn lots of attention and its security has been widely discussed and *** PqCrypto2019, Liu, et al. proposed two key recovery attacks against it. However, their first attack heavily relies on a weaken decryption oracle, and the second attack needs to collect about 260ciphertexts from the same message by theoretical analysis, which makes both of the attacks unrealistic. In this paper, inspired by the broadcast attack against NTRU, the authors find out that for NTRURe Encrypt the delegator and the delegatee can efficiently recover each other’s private key in polynomial time without any unrealistic assumptions. In addition, the authors also show how to fix NTRURe Encrypt to resist the proposed attacks. As a by-product, the authors also show how to commit broadcast attacks against NTRU 2001 with even dg, which was thought infeasible before.

关键词： Broadcast attack key recovery NTRU NTRUReEncrypt